Figure 3.

SHP2 inhibitor 11a-1 reduced lung cancer cell proliferation and specifically blocked SHP2-dependent signaling. (A) 11a-1 dose dependently inhibited H1975 proliferation with an IC₅₀ of 0.17 ± 0.02 μM. (B) 11a-1 decreased EGF induced Erk1/2 phosphorylation and increased EGF induced paxillin (Y118) phosphorylation in a dose-dependent manner. (C) The structurally related negative control 10a failed to block SHP2-dependent signaling at 2 μM. (D) the ability of 11a-1 to inhibit Erk1/2 activation was blunted in SHP2 knocked down cells, and (E) 11a-1 had no effect on PMA-stimulated Erk1/2 phosphorylation.